LCS
DNLI icon

Levin Capital Strategies’s Denali Therapeutics DNLI Stock Holding History

Levin Capital Strategies’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-24,000
Closed -$515K – 253
2023
Q4 		$515K Buy
24,000
+10,000
+71% +$198K 0.06% 138
2023
Q3 		$289K Buy
14,000
+6,500
+87% +$165K 0.04% 198
2023
Q2 		$221K Buy
+7,500
New +$211K 0.03% 206
2022
Q4 		– Sell
-9,500
Closed -$292K – 253
2022
Q3 		$292K Buy
9,500
+7,000
+280% +$228K 0.04% 157
2022
Q2 		$74K Buy
+2,500
New +$65.5K 0.01% 234

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $29.7B AUM 13.98% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return